Recently, promising results from a Phase 2 clinical study with dabrafenib, a BRAF inhibitor, has shown efficacy in the treatment of advanced NSCLC patients with V600E BRAF mutation (Figure 1) [48]. Here, BRAF is linked to non-small cell lung carcinoma.